Improved relative survival of patients with B-cell non-Hodgkin lymphoma in Queensland, 1993–2012

Ian N Olver
Med J Aust 2018; 209 (4): . || doi: 10.5694/mja18.00626
Published online: 20 August 2018

Monoclonal antibody-based therapies are improving outcomes for patients with a range of cancers

Anti-cancer immunotherapy, including monoclonal antibodies to specific cell surface protein antigens, is proving to be a successful strategy in the emerging era of personalised medicine. This issue of the Journal includes the report of a retrospective study of the impact of one of the first therapeutic monoclonal antibodies, rituximab, on the relative survival of patients with non-Hodgkin lymphoma in Queensland between 1993 and 2012.1 Rituximab binds the CD20 antigen that is found on 90% of B cells, making it easier for other immune system cells to eliminate the cancerous cells (antibody-dependent cell-mediated immunity).

  • Ian N Olver

  • Cancer Research Institute, University of South Australia, Adelaide, SA


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.